Status:
RECRUITING
Genomic Uniformed-Screening Against Rare Disease In All Newborns
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Illumina, Inc.
GeneDx
Conditions:
Early Onset Genetic Conditions With Near Complete Penetrance
Eligibility:
All Genders
1-1 years
Phase:
NA
Brief Summary
The goal of this study is to learn how genomic sequencing technology can be used to effectively expand the conditions screened on newborn screening. Newborn screening ensures equity and allows all bab...
Detailed Description
Newborn screening (NBS) is the process of screening all newborns for select conditions shortly after birth. This process reduces morbidity and mortality by the detection of medically actionable condit...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Newborns admitted to the well-baby nurseries from the recruiting hospitals
- Newborns born after 33 weeks of gestation
- Newborns whose parents are English, Mandarin, or Spanish speaking
Exclusion
Key Trial Info
Start Date :
September 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
100000 Patients enrolled
Trial Details
Trial ID
NCT05990179
Start Date
September 6 2022
End Date
September 1 2029
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center/NYP
New York, New York, United States, 10032